ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Linares L, Vinelli E, eds., 1994. Taller Latinoamericano de Servicios de Transfusión Sanguínea y óptimo uso de los Recursos. Caracas, Venezuela: Cruz Roja Finlandesa.
-
2
Schmunis GA, Zicker F, Pinheiro F, Brandling-Bennett D, 1998. Risk of transfusion transmitted infectious diseases in Central and South America. Emerg Infect Dis 4 :5–11.
-
3
Zuna H, La Fuente C, Valdez E, Recacochea M, Franco JL, Romero A, Bermudez H, 1985. Estudio prospectivo de la transmisión del Tripanosoma cruzi por vía sanguínea en Bolivia. Ann Soc Belg Med Trop 65 (Suppl. 1):107–113.
-
4
Carrasco R, Miguez H, Camacho C, Echalar L, Revollo S, Ampuero T, Dedet JP, 1990. Prevalence of Trypanosoma cruzi infection in blood banks of seven departments of Bolivia. Mem Inst Oswaldo Cruz 85 :69–73.
-
5
Landivar WHC, Nakasa T, Tachibana H, Paz KC, Tateno S, 1992. Seropositivity to Tryapanososma cruzi in blood donors in Santa Cruz, Bolivia. JID 166 :1464–1465.
-
6
Zuna H, Gianella A, 1991. 92/93. Infeccion por T. cruzi en donantes de sangre en Santa Cruz, Bolivia: (Influencia de la migracion). Bol Cient Centro Nacional de Enfermedades Tropicales 15 :60–64.
-
7
Miyoshi C, 1995. The cost effectiveness of blood donor screening programs to identify transfusion transmitted Chagas disease in Bolivia, including the use of a natural history model of Chagas’ disease. Takemi Program in International Health, Harvard School of Public Health.
-
8
Pan American Health Organization, 2005. Transfusion Medicine in the Caribbean and Latin American Countries, 2000–2003. Washington, DC: Pan American Health Organization.
-
9
Schmunis GA, Zicker F, Segura EL, Del Pozo AE, 2000. Transfusion-transmitted infectious diseases in Argentina, 1995 through 1997. Transfusion 40 :1048–1053.
-
10
Schmunis GA, Zicker F, Pinheiro F, Cruz JR, Cuchi P, 1991. Safety of blood supply for infectious diseases in Latin American countries, 1994–1997. Am J Trop Med Hyg 65 :924–930.
-
11
Schmunis GA, Cruz JR, 2005. Safety of the blood supply in Latin America. Clin Microbiol Rev 18 :12–29.
-
12
United States General Accounting Office, 1997. Report to the Ranking Minority Member Committee on Commerce, House of Representatives. Blood Supply. FDA Oversight and Remaining Issues of Safety. GAO/PEMED-97-1. Washington, DC: United States General Accounting Office.
-
13
WHO/UNAIDS, 1998. Operational Characteristics of Commercially Available Assays to Determine Antibodies to HIV-1 and/ or HIV- 2 in Human Sera. Report 9–10. Geneva: World Health Organization.
-
14
WHO/UNAIDS, 1999. Operational Characteristics of Commercially Available Assays to Determine Antibodies to HIV-1 and/ or HIV-2 in Human Sera. Report 11. Geneva: World Health Organization.
-
15
World Health Organization, 2001. Hepatitis B Surface Antigen Assays: Operational Characteristics. Report 1. Geneva: World Health Organization.
-
16
Couruce AM, Le Marrec N, Girault A, Ducamp S, Simon N, 1994. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialisis: comparison of second- and third-generation anti-HCV assays. Transfusion 34 :790–795.
-
17
Uttendaelle S, Claeys H, Mertens W, Verhaert H, Vermylen C, 1994. Evaluation of third generation screening and confirmatory assays for HCV antibodies. Vox Sang 66 :122–129.
-
18
Vrielink H, Reesink PJ, van den Burg PJM, Zaaijer HI, Cuypers HTM, Lelie PN, van der Poel CL, 1997. Performance of three generations of anti-hepatitis C virus enzyme-linked immuno-absorbent assays in donors and patients. Transfusion 37 :845–849.
-
19
World Health Organization, 2001. Hepatitis C Assays: Operational Characteristics (Phase 1). Report 2. Geneva: World Health Organization.
-
20
Qelemann WM, Teixeira MD, Verissimo da Costa GC, Borges-Pereira J, De Castro JDF, Coura JR, Peraltan JM, 1998. Evaluation of three commercial enzyme-linked immuno-sorbent assays for diagnosis of Chagas disease. J Clin Microbiol 36 :2423–2427.
-
21
Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, Faucett C, Fletcher MA, Kleiman SH, Operskalski EA, 1990. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Intern Med 113 :733–739.
-
22
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, 1996. The risk of transfusion-transmitted viral infections. N Engl J Med 334 :1685–1690.
-
23
Aach RD, Stevens CE, Hollinger FB, Mosley JW, Petersen DA, Taylor PE, Johnson RG, Barbosa LH, Nemo GJ, 1991. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first-and second-generation assays. N Engl J Med 325 :1325–1329.
-
24
World Health Organization, 1991. Control of Chagas disease. WHO Tech Rep Ser No. 811 :32.
-
25
Cerisola JA, Rabinovich A, Álvarez M, Di Corleto CA, Pruneda J, 1972. Enfermedad de Chagas y la transfusión de sangre. Bol. Ofic Sanit. Panam. 73 :203–221.
-
26
Attias A, Lorca M, Canales M, Mercado R, Reyes V, Child R, 1984. Chagas disease: transmission by blood transfusion in Chile. Bol Hosp San Juan de Dios (Santiago) 31 :301–306.
-
27
Lorca M, Lorca J, Child R, Attias A, Canales M, Lorca E, Gutiérrez J, 1988. Prevalencía de la infección por Trypanososma cruzi en pacientes politransfundidos. Rev Med Chil 116 :112–116.
-
28
Organización Panamericana de la Salud, 2003. Medicina Transfusional en América Latina 1994–2003. Document OPS/EV-LAB/01.2003. Washington, DC: OPS.
-
29
Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis WF, Notari EPI, 1995. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 333 :1721–1725.
-
30
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, 1996. The risk of transfusion-transmitted viral infections. N Engl J Med 334 :1685–1690.
-
31
Ministerio de Sanidad y Consumo, Direccion General de Salud Publica. Plan Nacional de Hemoterapia, 1998. Estadistica Estatal de Centros de Transfusion y Bancos de Sangre. Año 1997.
-
32
Sookvian S, Castano G, Castiglioni T, Pilar S, Videz P, Gonzalez J, Frider B, 1997. Problematica de la infeccion por el virus de la hepatitis C en donantes de sangre. Medicina (Buenos Aires) 55 :699–707.
-
33
Wendell S, Gonzaga A, 1993. Chagas’ disease and blood transfusion: a new world problem? Vox Sang 54 :1–12.
-
34
Salles N, Sabino EC, Cliquet MG, Eluf-Neto J, Mayer A, Almeida-Neto AC, Mendonca MC, Dorliach-Llacer P, Chamone DF, Saez-Alquezar A, 1996. Risk of exposure to Chagas disease among seroreactive Brazilian blood donors. Transfusion 36 :969–973.
-
35
Lorca M, Child R, Garcia A, Silva M, Osorio J, Atlas A, 1992. Evaluacion de reactivos comerciales empleados en el diagnosticode la enfermedad de Chagas en bancos de sangre de Chile. I. Selección de reactivos. Rev Med Chile 120 :420–426.
-
36
Lorca MH, Child RB, Garcia CA, Silva MG, Martinez LP, Jerez JM, Toledo ID, Mezzano DA, 1994. Evaluacion de reactivos comerciales empleados en el diagnostico de la enfermedad de Chagas en bancos de sangre de Chile. II Aplicación rutinaria. Rev Med Chile 122 :925–931.
-
37
Saez-Alquezar A, Luquetti AO, Borges Pereira J, Furtao EM, Gadelha MFS, Garcia-Zapata MT, Arruda AHS, 1997. Estudo multicentrico: avaliacao do desempenho de conjuntos diagnosticos de hemaglutinacao indireta, disponiveis no Brasil, para o diagnostico sorologico da infeccao pelo Trypanosoma cruzi.Rev Patol Trop. 26 :343–374.
-
38
World Health Organization, 2002. Control of Chagas disease. Geneva: World Health Organization.
-
39
Zuna H, Gianella A, 1991. 92/93. Enfermedad de Chagas en donantes de sangre en Santa Cruz de la Sierra. Bol Cient CENETROP 15 :65–69.
-
40
Bossuyt M, Torrez R, Coenen J, Herteleer J, 2002. Banco de Sangre Regional—Santa Cruz 1994–2002. Informe Final. Brussels, Belgium: Projecto Sistemas Locales de Salud Santa Cruz, Cooperacion Tecnica Belga.
-
41
Pinto Diaz JC, 2007. Southern Cone initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation, and perspectives. Mem Inst Oswaldo Cruz 102 (Suppl. 1):11–18.
-
42
Pan American Health Organization, 1999. Strengthening blood banks in the Region of the Americas. 124th Session of the Executive Committee. Resolution CD41 :R15.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 97 | 63 | 7 |
| Full Text Views | 248 | 3 | 0 |
| PDF Downloads | 46 | 3 | 0 |
Prevention of Blood-borne Diseases in Bolivia, 1993–2002
Gabriel A. Schmunis
Gabriel A. Schmunis
Pan American Health Organization/World Health Organization, Washington, DC; Regional Blood Bank, Santa Cruz, Bolivia; Institute of Tropical Medicine, Antwerp, Belgium; Pan American Health Organization, Guatemala City, Guatemala; National Center for tropical Diseases, Santa Cruz, Bolivia
Search for other papers by Gabriel A. Schmunis in
Current site
Google Scholar
PubMed
Search for other papers by Gabriel A. Schmunis in
Current site
Google Scholar
PubMed
Gloria Rodriguez
Gloria Rodriguez
Pan American Health Organization/World Health Organization, Washington, DC; Regional Blood Bank, Santa Cruz, Bolivia; Institute of Tropical Medicine, Antwerp, Belgium; Pan American Health Organization, Guatemala City, Guatemala; National Center for tropical Diseases, Santa Cruz, Bolivia
Search for other papers by Gloria Rodriguez in
Current site
Google Scholar
PubMed
Search for other papers by Gloria Rodriguez in
Current site
Google Scholar
PubMed
Jan Coenen
Jan Coenen
Pan American Health Organization/World Health Organization, Washington, DC; Regional Blood Bank, Santa Cruz, Bolivia; Institute of Tropical Medicine, Antwerp, Belgium; Pan American Health Organization, Guatemala City, Guatemala; National Center for tropical Diseases, Santa Cruz, Bolivia
Search for other papers by Jan Coenen in
Current site
Google Scholar
PubMed
Search for other papers by Jan Coenen in
Current site
Google Scholar
PubMed
Enrique Gil Bellorin
Enrique Gil Bellorin
Pan American Health Organization/World Health Organization, Washington, DC; Regional Blood Bank, Santa Cruz, Bolivia; Institute of Tropical Medicine, Antwerp, Belgium; Pan American Health Organization, Guatemala City, Guatemala; National Center for tropical Diseases, Santa Cruz, Bolivia
Search for other papers by Enrique Gil Bellorin in
Current site
Google Scholar
PubMed
Search for other papers by Enrique Gil Bellorin in
Current site
Google Scholar
PubMed
Alberto Gianella
Alberto Gianella
Pan American Health Organization/World Health Organization, Washington, DC; Regional Blood Bank, Santa Cruz, Bolivia; Institute of Tropical Medicine, Antwerp, Belgium; Pan American Health Organization, Guatemala City, Guatemala; National Center for tropical Diseases, Santa Cruz, Bolivia
Search for other papers by Alberto Gianella in
Current site
Google Scholar
PubMed
Search for other papers by Alberto Gianella in
Current site
Google Scholar
PubMed
This report shows the outcome of a coordinated effort by locals, foreign institutions, and an international agency, from 1996–2002, aimed at preventing transmission of blood-borne diseases in Santa Cruz, Bolivia. From 2001–2002, testing the donor pool for HIV prevented transfusion of 32 infected units and 29 infections. With 100% screening coverage, 196 hepatitis B virus (HBV)-infected units were discarded, and 177 infections of HBV were prevented between 1999 and 2002. Incomplete screening for hepatitis C virus (HCV) may have tainted nine units of blood and generated eight HCV infections in 1999. On the other hand, 600 units infected with HCV were discarded, and 540 HCV infections were prevented between 1999 and 2002. Screening for Chagas disease prevented transfusion of 10,661 tainted units and 2,133 infections from 1999 to 2002. From 1996–2002, the investment was US$1,108,000.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Linares L, Vinelli E, eds., 1994. Taller Latinoamericano de Servicios de Transfusión Sanguínea y óptimo uso de los Recursos. Caracas, Venezuela: Cruz Roja Finlandesa.
-
2
Schmunis GA, Zicker F, Pinheiro F, Brandling-Bennett D, 1998. Risk of transfusion transmitted infectious diseases in Central and South America. Emerg Infect Dis 4 :5–11.
-
3
Zuna H, La Fuente C, Valdez E, Recacochea M, Franco JL, Romero A, Bermudez H, 1985. Estudio prospectivo de la transmisión del Tripanosoma cruzi por vía sanguínea en Bolivia. Ann Soc Belg Med Trop 65 (Suppl. 1):107–113.
-
4
Carrasco R, Miguez H, Camacho C, Echalar L, Revollo S, Ampuero T, Dedet JP, 1990. Prevalence of Trypanosoma cruzi infection in blood banks of seven departments of Bolivia. Mem Inst Oswaldo Cruz 85 :69–73.
-
5
Landivar WHC, Nakasa T, Tachibana H, Paz KC, Tateno S, 1992. Seropositivity to Tryapanososma cruzi in blood donors in Santa Cruz, Bolivia. JID 166 :1464–1465.
-
6
Zuna H, Gianella A, 1991. 92/93. Infeccion por T. cruzi en donantes de sangre en Santa Cruz, Bolivia: (Influencia de la migracion). Bol Cient Centro Nacional de Enfermedades Tropicales 15 :60–64.
-
7
Miyoshi C, 1995. The cost effectiveness of blood donor screening programs to identify transfusion transmitted Chagas disease in Bolivia, including the use of a natural history model of Chagas’ disease. Takemi Program in International Health, Harvard School of Public Health.
-
8
Pan American Health Organization, 2005. Transfusion Medicine in the Caribbean and Latin American Countries, 2000–2003. Washington, DC: Pan American Health Organization.
-
9
Schmunis GA, Zicker F, Segura EL, Del Pozo AE, 2000. Transfusion-transmitted infectious diseases in Argentina, 1995 through 1997. Transfusion 40 :1048–1053.
-
10
Schmunis GA, Zicker F, Pinheiro F, Cruz JR, Cuchi P, 1991. Safety of blood supply for infectious diseases in Latin American countries, 1994–1997. Am J Trop Med Hyg 65 :924–930.
-
11
Schmunis GA, Cruz JR, 2005. Safety of the blood supply in Latin America. Clin Microbiol Rev 18 :12–29.
-
12
United States General Accounting Office, 1997. Report to the Ranking Minority Member Committee on Commerce, House of Representatives. Blood Supply. FDA Oversight and Remaining Issues of Safety. GAO/PEMED-97-1. Washington, DC: United States General Accounting Office.
-
13
WHO/UNAIDS, 1998. Operational Characteristics of Commercially Available Assays to Determine Antibodies to HIV-1 and/ or HIV- 2 in Human Sera. Report 9–10. Geneva: World Health Organization.
-
14
WHO/UNAIDS, 1999. Operational Characteristics of Commercially Available Assays to Determine Antibodies to HIV-1 and/ or HIV-2 in Human Sera. Report 11. Geneva: World Health Organization.
-
15
World Health Organization, 2001. Hepatitis B Surface Antigen Assays: Operational Characteristics. Report 1. Geneva: World Health Organization.
-
16
Couruce AM, Le Marrec N, Girault A, Ducamp S, Simon N, 1994. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialisis: comparison of second- and third-generation anti-HCV assays. Transfusion 34 :790–795.
-
17
Uttendaelle S, Claeys H, Mertens W, Verhaert H, Vermylen C, 1994. Evaluation of third generation screening and confirmatory assays for HCV antibodies. Vox Sang 66 :122–129.
-
18
Vrielink H, Reesink PJ, van den Burg PJM, Zaaijer HI, Cuypers HTM, Lelie PN, van der Poel CL, 1997. Performance of three generations of anti-hepatitis C virus enzyme-linked immuno-absorbent assays in donors and patients. Transfusion 37 :845–849.
-
19
World Health Organization, 2001. Hepatitis C Assays: Operational Characteristics (Phase 1). Report 2. Geneva: World Health Organization.
-
20
Qelemann WM, Teixeira MD, Verissimo da Costa GC, Borges-Pereira J, De Castro JDF, Coura JR, Peraltan JM, 1998. Evaluation of three commercial enzyme-linked immuno-sorbent assays for diagnosis of Chagas disease. J Clin Microbiol 36 :2423–2427.
-
21
Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, Faucett C, Fletcher MA, Kleiman SH, Operskalski EA, 1990. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Intern Med 113 :733–739.
-
22
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, 1996. The risk of transfusion-transmitted viral infections. N Engl J Med 334 :1685–1690.
-
23
Aach RD, Stevens CE, Hollinger FB, Mosley JW, Petersen DA, Taylor PE, Johnson RG, Barbosa LH, Nemo GJ, 1991. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first-and second-generation assays. N Engl J Med 325 :1325–1329.
-
24
World Health Organization, 1991. Control of Chagas disease. WHO Tech Rep Ser No. 811 :32.
-
25
Cerisola JA, Rabinovich A, Álvarez M, Di Corleto CA, Pruneda J, 1972. Enfermedad de Chagas y la transfusión de sangre. Bol. Ofic Sanit. Panam. 73 :203–221.
-
26
Attias A, Lorca M, Canales M, Mercado R, Reyes V, Child R, 1984. Chagas disease: transmission by blood transfusion in Chile. Bol Hosp San Juan de Dios (Santiago) 31 :301–306.
-
27
Lorca M, Lorca J, Child R, Attias A, Canales M, Lorca E, Gutiérrez J, 1988. Prevalencía de la infección por Trypanososma cruzi en pacientes politransfundidos. Rev Med Chil 116 :112–116.
-
28
Organización Panamericana de la Salud, 2003. Medicina Transfusional en América Latina 1994–2003. Document OPS/EV-LAB/01.2003. Washington, DC: OPS.
-
29
Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis WF, Notari EPI, 1995. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 333 :1721–1725.
-
30
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, 1996. The risk of transfusion-transmitted viral infections. N Engl J Med 334 :1685–1690.
-
31
Ministerio de Sanidad y Consumo, Direccion General de Salud Publica. Plan Nacional de Hemoterapia, 1998. Estadistica Estatal de Centros de Transfusion y Bancos de Sangre. Año 1997.
-
32
Sookvian S, Castano G, Castiglioni T, Pilar S, Videz P, Gonzalez J, Frider B, 1997. Problematica de la infeccion por el virus de la hepatitis C en donantes de sangre. Medicina (Buenos Aires) 55 :699–707.
-
33
Wendell S, Gonzaga A, 1993. Chagas’ disease and blood transfusion: a new world problem? Vox Sang 54 :1–12.
-
34
Salles N, Sabino EC, Cliquet MG, Eluf-Neto J, Mayer A, Almeida-Neto AC, Mendonca MC, Dorliach-Llacer P, Chamone DF, Saez-Alquezar A, 1996. Risk of exposure to Chagas disease among seroreactive Brazilian blood donors. Transfusion 36 :969–973.
-
35
Lorca M, Child R, Garcia A, Silva M, Osorio J, Atlas A, 1992. Evaluacion de reactivos comerciales empleados en el diagnosticode la enfermedad de Chagas en bancos de sangre de Chile. I. Selección de reactivos. Rev Med Chile 120 :420–426.
-
36
Lorca MH, Child RB, Garcia CA, Silva MG, Martinez LP, Jerez JM, Toledo ID, Mezzano DA, 1994. Evaluacion de reactivos comerciales empleados en el diagnostico de la enfermedad de Chagas en bancos de sangre de Chile. II Aplicación rutinaria. Rev Med Chile 122 :925–931.
-
37
Saez-Alquezar A, Luquetti AO, Borges Pereira J, Furtao EM, Gadelha MFS, Garcia-Zapata MT, Arruda AHS, 1997. Estudo multicentrico: avaliacao do desempenho de conjuntos diagnosticos de hemaglutinacao indireta, disponiveis no Brasil, para o diagnostico sorologico da infeccao pelo Trypanosoma cruzi.Rev Patol Trop. 26 :343–374.
-
38
World Health Organization, 2002. Control of Chagas disease. Geneva: World Health Organization.
-
39
Zuna H, Gianella A, 1991. 92/93. Enfermedad de Chagas en donantes de sangre en Santa Cruz de la Sierra. Bol Cient CENETROP 15 :65–69.
-
40
Bossuyt M, Torrez R, Coenen J, Herteleer J, 2002. Banco de Sangre Regional—Santa Cruz 1994–2002. Informe Final. Brussels, Belgium: Projecto Sistemas Locales de Salud Santa Cruz, Cooperacion Tecnica Belga.
-
41
Pinto Diaz JC, 2007. Southern Cone initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation, and perspectives. Mem Inst Oswaldo Cruz 102 (Suppl. 1):11–18.
-
42
Pan American Health Organization, 1999. Strengthening blood banks in the Region of the Americas. 124th Session of the Executive Committee. Resolution CD41 :R15.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 97 | 63 | 7 |
| Full Text Views | 248 | 3 | 0 |
| PDF Downloads | 46 | 3 | 0 |